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Abstract Peripartum cardiomyopathy (PPCM) is a life-
threatening heart disease developing towards the end of
pregnancy or in the months following delivery in previ-
ously healthy women in terms of cardiac disease. Enhanced
oxidative stress and the subsequent cleavage of the nursing
hormone Prolactin into an anti-angiogenic 16 kDa sub-
fragment emerged as a potential causal factor of the dis-
ease. We established a prospective registry with confirmed
PPCM present in 115 patients (mean baseline left ven-
tricular ejection fraction, LVEF: 27 ± 9 %). Follow-up
data (6 ± 3 months) showed LVEF improvement in 85 %
and full recovery in 47 % while 15 % failed to recover
with death in 2 % of patients. A positive family history of
cardiomyopathy was present in 16.5 %. Pregnancy-asso-
ciated hypertension was associated with a better outcome
while a baseline LVEF B 25 % was associated with a
worse outcome. A high recovery rate (96 %) was observed
in patients obtaining combination therapy with beta-
blocker, angiotensin-converting enzyme (ACE) inhibitors/
angiotensin-receptor-blockers (ARBs) and bromocriptine.
Increased serum levels of Cathepsin D, the enzyme that
generates 16 kDa Prolactin, miR-146a, a direct target of
16 kDa Prolactin, N-terminal-pro-brain-natriuretic peptide
(NT-proBNP) and asymmetric dimethylarginine (ADMA)
emerged as biomarkers for PPCM. In conclusion, low
baseline LVEF is a predictor for poor outcome while
pregnancy-induced hypertensive disorders are associated
with a better outcome in this European PPCM cohort. The
high recovery rate in this collective is associated with a
treatment concept using beta-blockers, ACE inhibitors/
ARBs and bromocriptine. Increased levels of Cathepsin D
activity, miR-146a and ADMA in serum of PPCM patients
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support the pathophysiological role of 16 kDa Prolactin for
PPCM and may be used as a specific diagnostic marker
profile.
Keywords Peripartum cardiomyopathy  Registry 
Prolactin  MicroRNA  Biomarker
Introduction
Peripartum cardiomyopathy (PPCM) is the major cause of
pregnancy-induced heart failure and is associated with high
morbidity and mortality [16, 19, 21, 24].
The true incidence of PPCM is unknown, as clinical
presentation varies. Current estimates ranging from 1:299
(Haiti), 1:1000 (South Africa) to 1:3186 in the USA are
primarily based on case series from single centres or ret-
rospective questionnaires [2, 3]. No data exists on the
frequency of the disease in Europe whose pathophysiology
remains still unclear with multiple factors likely to con-
tribute and to drive progression. Nevertheless, advances
have been achieved in understanding some underlying
molecular cascades deregulated in PPCM pointing to an
important role of an angiogenic imbalance caused by an-
giostatic and pro-apoptotic 16 kDa Prolactin fragment and
the soluble VEGF receptor 1 (sFlt1) which leads to massive
endothelial damage and myocardial dysfunction [9, 10, 15].
16 kDa Prolactin seems to mediate a large part of its anti-
angiogenic effects by the induction of microRNA-146a
(miR-146a) [9]. In endothelial cells miR-146a inhibits
proliferation and promotes apoptosis [9]. Moreover,
16 kDa Prolactin promotes shedding of miR-146a loaded
exosomes from endothelial cells that are absorbed by
cardiomyocytes where they impair metabolic activity [9], a
feature that is further supported by observations showing
that endothelial microparticles are increased in acute
PPCM [26]. Genetic factors may contribute to the sus-
ceptibility to PPCM in patients with positive family history
of cardiomyopathy, who typically have a more severe
course of disease [14, 25].
In order to gain further insight into the contemporary
epidemiology, diagnosis, etiology and management of
PPCM patients, we established a prospective registry for
PPCM cases between 2004 and 2012 in Germany with
patients who were newly diagnosed with PPCM according
to the definition proposed in a recent position paper from
the Heart Failure Association of the European Society of
Cardiology [24]: (1) PPCM is an idiopathic cardiomyop-
athy presenting with heart failure secondary to left ven-
tricular (LV) systolic dysfunction towards the end of
pregnancy or in the months following delivery, where no
other cause of heart failure is found; (2) it is a diagnosis of
exclusion with a left ventricular ejection fraction (LVEF)
nearly always reduced below 45 % but not always asso-
ciated with LV dilatation. From this first larger prospec-
tive German PPCM cohort we believe to gain novel
insights on etiology, risk factors, underlying pathophysi-
ology, co-morbidity, prognosis, biomarker profiles and




Our local Ethics Committee approved this study. Suspected
PPCM cases were reported to our registry from University
hospitals, tertiary hospitals or cardiologists in private
practice. All patients provided a written informed consent,
minimal requirement for enrolment was baseline LVEF
and close relationship to pregnancy (pregnant or delivery
up to 6 months ago); not all patients agreed to provide
probes and additional clinical data, a reason why not all
other data sets are complete in this registry. Clinical
assessments such as onset of symptoms and signs during
first presentation, New York Heart Association (NYHA)
functional class, ECG, echocardiographic analyses, family
history, diseases in pregnancy and mode of delivery were
obtained from the patients, the referring physician and by
examining the obstetric cards and medical records. Clinical
and laboratory assessments were performed in 115 patients
with confirmed PPCM at time of diagnosis and in a subset
of patients (n = 96) at 6 ± 3-month follow-up.
The control collective consisted of healthy postpartum
women with confirmed normal cardiac function (echo-
cardiography, LVEF [ 55 %, n = 19) in the first post-
partum week when also plasma and serum probes were
collected.
Medication
Standard medication for heart failure was applied upon
diagnosis and reported. A positive record with the healing
attempt using bromocriptine therapy (BR therapy) was
noted if a patient obtained bromocriptine according to the
protocol published in our pilot study [20] which is based
on an efficient suppression of Prolactin by 2.5–5 mg
bromocriptine per day for at least 4 weeks together with
beta-blocker and angiotensin-converting enzyme (ACE)
inhibitor/angiotensin-receptor-blockers (ARBs) or other
heart failure therapy according to the guidelines. Patients
who did not obtain this bromocriptine therapy protocol but
got the standard therapy for heart failure according to the
guidelines were defined as the non-BR group. There was no
randomization of patients to either group.
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Blood tests
Blood samples were collected at the time point of first
diagnosis (baseline) and at the follow-up visit (6 ± 3
months after diagnosis) in S-Monovette tubes containing
ethylenediaminetetraacetic acid (EDTA) or clot activator,
respectively. Plasma and serum were separated by centri-
fugation at 1,500 rpm for 10 min. Aliquots were stored at
-80 C for future analysis. Laboratory workup was per-
formed as routine investigation by hospital laboratories for
Prolactin (Prolactin kit, Roche), N-terminal pro-brain
natriuretic peptide (NT-proBNP), C-reactive protein
(CRP), Thyroid stimulating hormone (TSH), total choles-
terol, Troponin T (TnT), Creatine kinase (CK), Hemoglo-
bin (Hb), full blood count, liver function, and Creatinine.
Analysis of serum asymmetric dimethylarginine
(ADMA)
Concentrations of serum ADMA were determined by gas
chromatography-tandem mass spectrometry (GC-tandem
MS) [8].
Measurement of Cathepsin D
Serum Cathepsin D activity was evaluated with the Sens-
olyte 520 Cathepsin D Assay Kit (MoBiTec) as previously
described [10].
RNA extraction and miRNA expression analysis
in the plasma by TaqMan MicroRNA Assay
Total RNA extraction was performed with the miRNeasy
kit (Qiagen). Taqman methods were used to assess miRNA
expression as previously described [9]. Briefly, RNA from
100 ll of serum was reverse transcribed to cDNA with the
Taqman microRNA Reverse Transcription kit and the
Taqman microRNA assay stem loop primers (Applied
Biosystems). Resulting cDNAs were used for quantitative
real-time PCR using Taqman microRNA assay and Taq-
man universal PCR master mix reagents (Applied Biosys-
tems). Thermal cycling was performed on an Applied
Biosystem 7900 HT detection system (Applied Biosys-
tems). The relative miRNA levels were then normalized to
two spikes-in miRNAs: cel-miR-39 and cel-miR-238
(Applied Biosystems).
Analysis of outcome
After follow-up at 6 ± 3 months, patients were classified
as described previously [5, 20, 23]. In brief, patients were
classified as improvers (IMP) if LVEF increased by 10
absolute percent units or if NYHA improved by one class.
Patients were classified as non-improvers (NIMPs) if they
showed at the follow-up visit any of the parameters such as
an LVEF \ 35 %, failed to improve LVEF by 10 absolute
units, remained at a NYHA functional class of III/IV or
obtained heart transplantation or had died. Full recovery
was defined as reaching an LVEF of C55 % and NYHA
class I to II.
Statistical analysis
Database management and statistical analyses were per-
formed with SAS software, version 9.2 statistical program
(SAS, Institute Inc., Cary, North Carolina, USA). Contin-
uous data were expressed as mean ± SD or median and
range. Comparison of means and proportions between sub-
groups at baseline was performed by independent t test and
Chi-square statistics, or Fisher exact test where necessary,
respectively. Wilcoxon rank-sum test was used if data were
not normally distributed. Significance was assumed at a
two-sided value of p \ 0.05.
Results
Onset and diagnosis of PPCM
Between 2004 and 2012 176 patients with suspected PPCM
were reported to the German PPCM registry of whom a total
of 115 patients matched the diagnostic criteria defined by
Sliwa et al. [24] while 61 patients did not meet the diag-
nostic criteria, i.e., EF B 45 % and absence of previously
known cardiomyopathy. Mean LVEF at the time of diag-
nosis was 27 ± 9 %. LV dilatation (LVEDD [ 56 mm)
was present in 72 % (54/75) indicating that LV was not
dilated in 28 % of patients at the time of diagnosis. All other
clinical and serum parameters of all patients if available are
indicated in supplementary material Table S1.
Records on the time of diagnosis in relation to delivery,
i.e., the last month of pregnancy, at delivery, the first
month, 2–3 months, or later than 3 months after delivery
were available from 90 patients. Most patients were diag-
nosed at delivery or in the first postpartal month (Fig. 1).
Diagnosis prior delivery was made in 6 % (5/90 patients)
between gestational week 28 and 36 followed by delivery
within 1 day to 4 weeks. One patient with the anti-
phospholipid syndrome developed PPCM after a miscar-
riage in the second trimester during the first pregnancy. A
second patient with lupus erythematosus developed PPCM
after a miscarriage in the first trimester. The median gravity
was 2 (range 1–11) and the median parity was 2 (range
0–9) (supplementary material Table S1), with 36 % (35/96)
being primipara.
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Risk factors and co-morbidities in PPCM patients
Information on risk factors and co-morbidities from PPCM
patients were compared to healthy postpartum controls
(n = 19, mean LVEF of 62 ± 4 %, range: 57–70 %) and,
if available, to data from the general population in Ger-
many (Table 1). PPCM patients tended to be older than the
control collective and the average child-bearing woman in
Germany (Table 1). Parity in PPCM patients was higher
than in women of the control collective but similar to the
overall parity in women in Germany (Table 1). The inci-
dence of cesarean section (C-section) was significantly
higher in PPCM patients compared to controls (p \ 0.01),
albeit also our control collective had a higher rate com-
pared to the overall rate in Germany (Table 1). Emergency
C-section was performed in 12.5 % (8 of 64 C-sections) of
PPCM patients. We excluded patients with pregnancy-
induced hypertensive disorders (HT: hypertension, pre-
eclampsia and/or HELLP: HELLP-Syndrome: Hemolysis
Elevated Liver enzymes Low Platelet count) in our post-
partum controls, so valid comparison for this parameter is
only possible to the overall frequency in Germany, which
shows that the frequency of HT in our PPCM collective is
higher (Table 1). There was a tendency for more smokers
and more pathologic conditions of thyroid gland, while the
incidence in gestational diabetes was similar in PPCM
patients compared to controls and the overall population in
Germany (Table 1). Previous chemotherapy due to child-
hood malignancies was reported in 1 of the 115 patients
and in none of the controls.
Biomarker profiles in patients with acute PPCM
compared to healthy postpartum controls
Serum analyses showed that TnT was within normal range
in the majority of PPCM patients (Fig. 2a, supplementary
material Table S1). CK was up-regulated in 37 % of PPCM
patients but is also frequently up-regulated in healthy
peripartum women [17] (Fig. 2a, b, supplementary material
Table S1). Likewise, CRP was increased in the majority of
healthy postpartum controls and in several PPCM patients
but was normal in others (Fig. 2a, supplementary material
Table S1). NT-proBNP, a marker for heart failure, was
increased in almost all PPCM patients but rarely in healthy
postpartum controls (Fig. 2a, b, supplementary material
Table S2). ADMA is a known marker for hypertensive
complications in pregnancy such as preeclampsia [18], a
pregnancy complication frequently present in our PPCM
collective. Cathepsin D has been shown to be elevated in a
small collective of PPCM patients [10]. Serum levels of
Table 1 Comparison of factors for lifestyle, cardiovascular risk and pregnancy related conditions between PPCM patients, healthy postpartum
controls and the general population in Germany
PPCM Controls German statistical data
Age (years) (mean ± SD) 34 ± 6 (n = 113) 29 ± 5 (n = 19) 30a
Parity Median (range) 2 (0–9) (n = 97) 1 (1–3) (n = 19) 1.9a
Twin pregnancy 15 % (n = 17/110) 11 % (n = 2/19) 1.6 %b
C-section* 68 % (n = 64/94) 26 % (n = 5/9) 31.9 %a
Pregnancy-induced hypertensive disorders 45 % (n = 50/112) 0 % (n = 0/19) 1–5 %c
Smoking 45 % (n = 32/71) 26 % (n = 5/19) 25 %a
Pathologic condition of thyroid gland 23 % (n = 16/69) 11 % (n = 2/19)
Gestational diabetes 7 % (n = 8/115) 11 % (n = 2/19) 3.7 %d
Tocolysis 4 % (n = 5/115) 0 % (n = 0/19)
C-section cesarean section
* p \ 0.01 PPCM vs. healthy postpartum controls
Data for the overall population in Germany were obtained from a the Federal Statistical Office (https://www.destatis.de/DE/Publikationen/
Thematisch/Bevoelkerung), bhttp://de.statista.com/statistik/daten/studie/1281/umfrage/anzahl-der-zwillingsgeburten-in-deutschland-2006/,
c http://www.hochdruckliga.de, dhttp://www.deutsche-diabetes-gesellschaft.de/
Fig. 1 Time of diagnosis in relation to delivery in PPCM patients
n = 90
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ADMA and Cathepsin D activity were significantly higher
in PPCM patients compared to postpartum controls, but
both markers showed a broad range of overlapping values
between the two groups (Fig. 2c, d, supplementary material
Table S2). Stratification of ADMA serum levels in Quar-
tiles (cut-off values: 1st Quartile: 0.52 lmol/l; 2nd Quar-
tile: 0.59 lmol/l; 3rd Quartile: 0.69 lmol/l; 4th Quartile:
0.85 lmol/l) showed that the portion of the patients with a
full recovery gradually decreased from the 2nd to the 4th
quartile, albeit with no significant differences (supple-
mentary material Fig. 1). We recently reported that 16 kDa
Prolactin induces miR-146a expression in endothelial cells
and showed that it is up-regulated in a small collective of
PPCM patients [9].
Here we observed increased serum levels of miR-146a in
57 PPCM patients at baseline compared with 19 pregnancy-
matched healthy postpartal women (Fig. 3a). Furthermore,
we found that PPCM patients who were already treated for
3–7 days with bromocriptine before the initial diagnosis of
PPCM was made and the baseline blood sample was col-
lected displayed significantly lower miR-146a levels as
compared to not-treated patients (Fig. 3a), while LVEF and
NT-proBNP levels were not yet changed (Fig. 3b, c).
Follow-up analyses in PPCM patients
Follow-up data for 6 ± 3 months on LVEF were avail-
able for 96 patients while 19 patients were lost to follow-
up. The mean follow-up LVEF increased from 27 ± 9 to
47 ± 19 %. The majority of patients were defined as
improvers (IMP, 85 %, 82/96), which according to our
pre-specified criteria (see material and method section)
include partial recovery and full recovery. In 47 %
(45/96) of patients, full recovery with an LVEF C 55 %
and NYHA class I to II was observed. Of the 15 % (14/
96) patients classified as non-improvers (NIMP), 4
patients displayed a follow-up LVEF \ 30 %, 1 patient
needed a left ventricular assist device (LVAD), and 7
patients obtained heart transplantation (HTX). Two
patients died, 1 of them after transplantation and 1 due to
sudden cardiac death. Eight patients obtained an
implantable cardioverter-defibrillator (ICD), 5 patients in
the IMP and 3 patients in the NIMP group. Defibrillator
life vests were used in 2 patients in the IMP (both
patients recovered and did not need ICDs) and 1 patient
in NIMP group (ICD was implanted after an episode of
ventricular fibrillation).
Fig. 2 a Percentage of PPCM patients with normal (TnT normal
\0.01 lg/l, NT-proBNP normal in women \146 lg/l, CK normal in
women \145 U/l, CRP normal \8 mg/l) and with pathophysiologic
relevant serum levels of TnT (n = 49), CK (n = 63), NT-proBNP
(n = 69) and CRP (n = 72) at the time of diagnosis. Baseline serum
levels of b NT-proBNP (PPCM, n = 69; control, n = 19), c ADMA
(PPCM, n = 34; control, n = 19) and d Cathepsin D (PPCM,
n = 43; Control, n = 19). p value compares PPCM vs. healthy
postpartum controls
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Subsequently, we compared baseline characteristics
between IMP and NIMP and found that in NIMP baseline
LVEDD was larger and baseline LVEF was lower com-
pared to IMP (p \ 0.0001, Table 2). In fact baseline LVEF
in all NIMPs was B25 %. In addition, baseline AST and
GGT were higher in NIMP compared to IMP (p = 0.006
and p = 0.004, Table 2). In addition, no significant dif-
ferences between IMP vs. NIMP were observed with regard
to co-morbidities such as smoking, gestational diabetes,
mode of delivery, older age, low Hb and hypothyroidism
(Table 2). Significantly more patients in the IMP group
reported pregnancy-associated hypertension compared to
NIMP (HT in IMP: 49 % 40/82 vs. HT in NIMP: 7 %,
1/14, p = 0.009, Table 2).
Clinical presentation and serum marker profiles
in PPCM patients with and without hypertensive
conditions during pregnancy
The differences in the incidence of hypertensive conditions
between IMP and NIMP prompted us to evaluate whether
patients with HT may display a different clinical presen-
tation at baseline compared to patients without HT. As
shown in the supplementary material Table S3 only NT-
proBNP levels were slightly but significantly higher in
PPCM patients with HT compared to PPCM without HT
conditions during pregnancy (p = 0.039). All other
parameters investigated at the time point of PPCM diag-
nosis such as gravida, para, NYHA, blood pressure (high
blood pressure in the hypertensive group was diagnosed
during pregnancy and treated), LV dimension, LV func-
tion, heart rate, ADMA, Prolactin and total cholesterol and
other serum markers did not differ between the two groups
(supplementary material Table S3).
Recovery rate in PPCM patients with a positive family
history of cardiomyopathy
A positive family history of cardiomyopathy (PPCM, DCM,
sudden death, arrhythmias in first degree relatives) was repor-
ted in 16.5 % (19/115) of PPCM patients with a baseline LVEF
of 25 ± 6 %. Recovery rate of patients with positive family
history of cardiomyopathy was similar to patients without such
a history of follow-up data: 82 % (14/17) improved with
complete recovery in 47 % (8/17). There is a tendency that
more of these patients (18 %, 3/17) needed a HTX compared to
patients with no reported family history of cardiomyopathies
(5 %, 4/79), albeit no significancy is reached.
Fig. 3 a Bar graph displaying elevated serum levels of miR-146a of
patients with acute PPCM without bromocriptine (n = 40) compared
with healthy postpartal controls (n = 19) and with acute PPCM
patients who obtained already bromocriptine (BR) for 3–7 days when
blood samples were taken (n = 17). b Bar graph showing baseline
LVEF and c NT-proBNP in the same PPCM patients with or without
early bromocriptine (BR) treatment. **p = 0.001 vs. Control
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Follow-up related to medical therapy
Records on medical history implemented after diagnosis were
available in all 96 patients with follow-up data. With regard to
standard therapy for heart failure, our analysis revealed that
more IMP obtained beta-blockers and/or ACE inhibitors/
angiotensin-receptor-blockers (ARB) compared to the NIMP
(Table 3). In addition, a high percentage of patients (67 %,
64/96) obtained bromocriptine according to the protocol we
have published in our pilot study [20] (BR group, methods
section), the overall percentage of IMP and of NIMP who
obtained bromocriptine is shown in Table 3. There was a
significantly higher percentage of patients classified as IMP
(92 %, 59/64) and a lower percentage classified as NIMP
(8 %, 5/64) in the BR group compared to the non-BR group
(IMP: 72 %, 23/32, NIMP: 28 %, 9/32). The percentage of
patients experiencing full recovery (LVEF C 55 % with
NYHA class I to II) was similar in both groups with no dif-
ference in baseline characteristics (supplementary material




Data for all patients with
follow-up classified as IMP or
NIMP are provided at baseline
with the number of patients
(n) analyzed behind each
values. p value compare IMP vs.
NIMP, parameters with N/A
indicated that meaningful
comparison was not possible
due to low number of data sets
Variables Number of
patients
IMP NIMP p value IMP
vs. NIMP
Age (years) (mean ± SD) 95 34 ± 6 (n = 81) 33 ± 4 (n = 14) 0.42
Gravida Median (range) 83 2 (1–11) (n = 72) 2 (1–3) (n = 11) 0.74
Parity Median (range) 83 2 (0–8) (n = 70) 2 (1–3)(n = 13) 0.60
Hypertensive disorder in
pregnancy
96 49 % (n = 40 of
82)
7 % (n = 1 of
14)
0.009
NYHA: n (%) 84 0.06
n: II n = 13 (18 %) n = 0 (0 %)
n: III n = 28 (40 %) n = 2 (15 %)
n: IV n = 30 (42 %) n = 11 (85 %)
Heart rate bpm (mean ± SD) 60 94 ± 27 (n = 52) 104 ± 19
(n = 8)
0.16
LVEDD (mm) (mean ± SD) 66 59 ± 7 (n = 55) 70 ± 8 (n = 11) 0.002
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patients, 96 % (55/57) who had obtained all three drugs, beta-
blockers, ACE inhibitors/ARBs and bromocriptine were
IMPs. In turn, only 14 % (2/14) of NIMP patients had
obtained the triple therapy.
Discussion
This report documents the first prospective multicenter
registry of 115 newly diagnosed PPCM patients in
Germany spanning a recent observation period from 2004
to 2012. It is one of the largest prospective cohort studies
of PPCM patients on contemporary management and
shows the association of baseline LVEF and pregnancy-
associated hypertension for prognosis. The study supports
the idea that PPCM might be provoked by pathogenic
factors including pregnancy-induced hypertension and
smoking and it elucidates the potential value of markers
such as NT-proBNP, Cathepsin D, ADMA and miRNA-
146a as markers for diagnosis and disease monitoring.
Moreover, increased plasma levels of Cathepsin D, ADMA
and miRNA-146a support the hypothesis that a circuit
involving Prolactin cleavage and subsequent endothelial
dysfunction acts as a major pathophysiological concept for
this disease. Finally, it is the largest cohort treated with the
novel disease specific therapy concept using the Prolactin
blocker bromocriptine in addition to the standard therapy
for heart failure aiming to block potential adverse effects of
the angiostatic 16 kDa Prolactin. It supports a potential
benefit of a treatment concept with bromocriptine, beta-
blockers and ACE inhibitors/ARBs but points also out that
it may not be sufficiently effective in all patients, especially
in PPCM patients with very low baseline EF.
Most patients were diagnosed at delivery or in the first
postpartum month, an observation that is similar to findings
from studies on a South African population [22] and from a
study from Haiti [4] documenting almost no patient with
signs of heart failure during the pre-partum period but
different to reports from PPCM collectives in the USA [3]
and Japan [12]. However, it is likely that in some patients
symptoms of heart failure were present earlier, i.e., during
pregnancy prior the initial diagnosis. This feature could not
be addressed properly in this study but warrants random
screening efforts in pregnant women, especially in such
with a high risk profile including smoking, pregnancy-
associated hypertension, twin pregnancy and older age. In
addition, the observation that onset of PPCM occurred also
in patients after fetal loss earlier in pregnancy suggests that
PPCM may not be linked exclusively to full-term preg-
nancies but to changes in the maternal physiology around
the time of delivery.
Numerous factors predicting a higher risk for develop-
ing PPCM have previously been proposed such as older
age, multiparty, obesity, smoking, delayed diagnosis, being
of African descent and preeclampsia [3, 19, 21]. In our
study, a history of smoking was present in almost half of
PPCM patients while only one forth of our control post-
partum collective and of women in the same age group
in accordance to data of the ‘‘Statistische Bundesamt’’
(http://www.gbe-bund.de/) were smokers suggesting that
smoking may increase the risk for PPCM. The mean age of
PPCM patients was higher compared to the average age of
child-bearing mothers in Germany and to the average age
of our control collective which is in line with previous
reports that older age appears to be a risk factor for the
disease. Two third of PPCM patients developed the disease
in a subsequent pregnancy, and the percentage of twin
pregnancies, albeit similar in our control collective, was
also higher in the PPCM collective compared to the overall
frequency in Germany, confirming previous observation
that the risk for PPCM increases with multiple parities and
twin pregnancies [21, 24]. Interestingly, gestational dia-
betes was not more frequent in PPCM compared to the
frequency in normal pregnancies in Germany. The number
of patients with tocolysis or childhood chemotherapy was
too low so no statement on these risk factors can be made
in our collective. Taken together, this risk factor analysis
further underline the importance of an adequate cardiac
monitoring during pregnancy especially in women with
pregnancy-associated hypertension, older age, or smokers.
The mode of delivery is also discussed as a potential risk
factor and indeed we observe that the frequency of cesar-
ean section was doubled in PPCM patients compared to the
overall frequencies reported in Germany. We cannot dis-
tinguish whether C-section may be a risk factor or whether
the clinical condition of PPCM patients may more fre-
quently be an indication for a C-section. However, it can be
speculated that a higher degree of cell traffic between the
baby and the mother takes place in C-section deliveries,
which may increase the incidence of PPCM based on
immune reaction.
Recently, several studies reported that PPCM occurred
in patients, who had a positive family history of cardio-
myopathies suggesting that the pregnancy/peripartum
stress may have demasked a genetic form of cardiomyop-
athy [14, 25]. Indeed, 16.5 % of PPCM patients in our
registry reported a positive family history of cardiomyop-
athy supporting the idea that genetic factors may be
involved in some PPCM patients. We observed that the
number of HTX was more than 3 times higher in these
patients, albeit not significant but nevertheless suggesting
that they may be more refractory to medical therapy and
tend to have a more severe course of disease [15, 16]. This
observation if confirmed in larger collectives could be
important for risk stratification and management of these
patients. However, the majority of our patients had no
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family history of cardiomyopathies and displayed an
apparently unremarkable cardiac condition prior to preg-
nancy suggesting that a genetic predisposition towards
heart failure appears to be rather rare in this cohort.
One of the most striking findings from this analysis is
the poor prognosis of patients with very low baseline
LVEF (\25 %) compared to patients with higher baseline
LVEF despite fairly high adherence to guideline-indicated
pharmacological therapy, although the optimum doses
were not reached in all cases. This observation strongly
suggests that initial LVEF is an important determinant of
prognosis, a notion that is in line with observations in
PPCM patients from South Africa [5, 21, 23] and from the
USA [7]. However, also in our cohort patients with base-
line LVEF \ 25 % had the potential to recover. Therefore,
we agree with Goland et al. [6] and discourage from using
baseline LVEF alone as an indication for premature use of
aggressive therapy such as assist device implantation or
HTX. In contrast with the African collective [5], we did not
find a correlation between poor outcome and high NT-
proBNP levels. It is also important to note that more IMPs
obtained beta-blockers and ACE inhibitors/ARBs com-
pared to the NIMPs, albeit this observation may also be due
to better hemodynamic conditions of the IMP in general
allowing to add beta-blocker therapy, whereas the non-
improvers more often presented with low blood pressure
and bradycardia impeding the application of beta-blockers.
One reason for poor outcome in PPCM could be skep-
ticism of physicians to consider the diagnosis of PPCM in
patients with symptoms of heart failure in the peripartal
phase who had no previous history of heart disease. Spe-
cific biomarkers for PPCM are scarce. Typical markers for
cardiac injury or inflammation are either frequently not up-
regulated, i.e., TnT or are up-regulated also in healthy
postpartum women, i.e., CK [17] and CRP. Although NT-
proBNP as a classical, yet unspecific biomarker for heart
failure was elevated in almost all patients, it is not suited to
differentiate between PPCM and other causes of heart
failure.
Therefore, we specifically investigated potential bio-
markers that would be associated with suspected patho-
physiological mechanisms present in PPCM. This profile
includes beside the classical biomarker for heart failure,
NT-proBNP, novel markers, which were driven from
findings of experimental studies such as Cathepsin D,
ADMA and miR-146a. For Cathepsin D, we showed that it
Table 3 Medication in PPCM
of patients with regard to
recovery
Medical history for all patients
with follow-up, classified as
IMP or NIMP, are provided
with the number of patients
(n) analyzed behind each
values. p value compare IMP








p value IMP vs.
NIMP
Bromocriptine 72 (n = 59) 35 (n = 5) 67 (n = 30) 0.013
Beta-blockers 95 (n = 78) 50 (n = 7) 93 (n = 42) 0.0001
Bisoprolol 29 (n = 24) 29 (n = 4) 24 (n = 11)
Metoprolol 51 (n = 42) 21 (n = 3) 55 (n = 24)
Carvedilol 13 (n = 11) 0 11 (n = 5)
Esmolol 1 (n = 1) 0 2 (n = 1)
ACE Inhib or ARB 93 (n = 76) 71 (n = 10) 91 (n = 41) 0.04
ACE Inhib 84 (n = 69) 64 (n = 9) 80 (n = 36) 0.16
ARB 11 (n = 9) 8 (n = 1) 14 (n = 6) 0.97
Ramipril 73 (n = 58) 54 (n = 7) 68 (n = 30)
Enalapril 8 (n = 7) 0 11 (n = 5)
Lisinopril 1 (n = 1) 0 0
Candesartan 6 (n = 5) 7 (n = 1) 7 (n = 3)
Irbesartan 1 (n = 1) 0 0
Valsartan 2 (n = 2) 0 4 (n = 2)
Telmisartan 1 (n = 1) 0 2 (n = 1)
MRA 65 (n = 53) 57 (n = 8) 56 (n = 25) 0.81
Eplerenone 7 (n = 6) 7 (n = 1) 7 (n = 3)
Spironolactone 57 (n = 47) 50 (n = 7) 45 (n = 22)
Diuretics 76 (n = 62) 86 (n = 12) 65 (n = 29) 0.51
Loop-Diuretics 70 (n = 57) 71 (n = 10) 53 (n = 24)
Thiazide 13 (n = 10) 15 (n = 2) 18 (n = 8)
Digitalis 5 (n = 4) 21 (n = 3) 4 (n = 2) 0.06
Digoxin 2 (n = 2) 21 (n = 3) 2 (n = 1)
Digitoxin 2 (n = 2) 0 2 (n = 1)
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is activated in the myocardium in an animal model of
PPCM in response to conditions of enhanced oxidative
stress during pregnancy in case of defective anti-oxidative
mechanisms. Activated Cathepsin D in turn leads to pro-
teolytic cleavage of nursing hormone Prolactin into a
16 kDa fragment that exerts anti-angiogenic effects [10].
The observation that Cathepsin D activity was significantly
higher in PPCM patients compared to postpartum controls
not only suggests Cathepsin D as a potential biomarker for
PPCM but also supports the findings from the experimental
studies (Fig. 4). More recently, we reported that 16 kDa
Prolactin induces the expression of miR-146a in endothe-
lial cells and showed that miR-146a is mediating most of
the anti-angiogenic effects of 16 kDa in endothelial cells
[9]. In addition, 16 kDa Prolactin triggers the release of
miR-146a-loaded exosomes from endothelial cells which
are absorbed by cardiomyocytes where they substantially
alter gene expression, i.e., ErbB4 and as a consequence
metabolic activity [9]. We reported a specific increase of
miR-146a in the serum of a small group of PPCM patients
compared to healthy postpartum controls and patients with
dilated cardiomyopathy [9], a feature that fits well to our
other observation that endothelial microparticles are highly
specifically increased in serum of PPCM patients [26].
Here we confirm the specific up-regulation of miR-146a in
our collective of PPCM patients compared to healthy
postpartum controls. In addition, patients with early bro-
mocriptine treatment displayed normalized miR-146a
serum levels while cardiac function and the heart failure
marker NT-proBNP were not different to untreated patients
at baseline. This observation further supports the patho-
physiologic connection of miR-146a with 16 kDa Prolactin
in the human PPCM disease and suggests that bromocrip-
tine treatment is highly efficient to clear the system from
16 kDa Prolactin and its downstream effectors.
ADMA, a marker of endothelial dysfunction and a
consequence of oxidative stress, was significantly higher in
serum from PPCM patients compared to healthy post-
partum women thereby supporting the idea of substantial
endothelial dysfunction in PPCM. Moreover, this obser-
vation adds ADMA to the pool of potential biomarkers for
PPCM. Elevated ADMA levels have been reported to be
associated with an enhanced risk of developing pre-
eclampsia [18], a feature that is quite interesting in the
view that hypertensive complications such as preeclampsia
were quite prominent in our PPCM collective. However,
ADMA has also been shown to be elevated in patients with
ischemic and dilated cardiomyopathy limiting its potential
to differentiate between different causes of heart failure
[1].
In summary, the biomarker profile described in this
study, i.e., Cathepsin D, miR-146a, ADMA and NT-
proBNP seem to support the idea that a circuit of
unbalanced oxidative stress, activated Cathepsin D and
subsequent cleavage of Prolactin in its 16 kDa form is a
driving force for the development of PPCM. This concept
is further supported by the finding that baseline Prolactin
levels were higher in patients with a poor outcome in our
cohort, but the numbers are too low to be conclusive.
However, the highest recovery rate was observed among
patients who obtained the Prolactin blocker bromocriptine
in addition to beta-blockers and ACE inhibitors/ARBs.
Recent experimental and clinical studies [15] reported
that pregnancy-induced hypertensive conditions such as
preeclampsia may be a risk factor for PPCM by providing
an extremely anti-angiogenic environment which may
include sFlt1 and 16 kDa Prolactin. Indeed, high levels of
sFlt-1 after delivery may be an additional factor that trig-
gers PPCM after preeclampsia [15], a feature that is cur-
rently investigated in larger PPCM collectives. Similar to a
PPCM collective described in Japan [12], we found a high
incidence of hypertensive conditions. In fact, one patient
with severe preeclampsia, who had documented normal
cardiac function prior delivery, developed PPCM after
delivery further emphasizing that preeclampsia may sen-
sitize for PPCM. Also similar to the Japanese collective
[12] is our observation that PPCM with concomitant
hypertension was associated with a higher recovery rate.
This feature is in accordance with the association of ele-
vated blood pressure and a better outcome in patients with
acute heart failure [13], and will be investigated more
closely in the future. In the African cohort, study patients
with [160 mmHg systolic and [110 mmHg diastolic
blood pressure were always excluded as the authors felt
that hypertensive heart disease in particular in African
women can per se lead to systolic dysfunction via a pos-
sibly different pathomechanism [22]. The German cohort is
therefore not fully comparable with the African cohort
studies as the inclusion and exclusion criteria are different.
In contrast to most other studies on outcome in PPCM
patients, a high percentage of patients in our cohort was
treated with the Prolactin blocker bromocriptine in addition
to standard treatment for heart failure [10, 11, 20]. Most of
these patients obtained beta-blockers and ACE inhibitors/
ARBs in addition to bromocriptine while most of NIMP
patients did not obtain this drug combination. This obser-
vation suggests that patients obtaining the combination of
these three medications may have a higher chance for
recovery (partial and full recovery). In parallel to the
general recommendations in all patients with systolic heart
failure, beta-blockers and/or ACE inhibitors/ARBs seem to
be highly beneficial and should always be considered early
in the treatment of PPCM with uptitration to the maximum
tolerated dose. The question whether bromocriptine on top
of these standard therapeutics has an additional benefit
cannot be answered by this observational trial. Therefore, it
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is necessary to test the BR therapy concept in controlled
randomized multicenter trials as the one that is currently
performed in Germany (randomization of 60 PPCM
patients to BR therapy or no BR therapy, study registered
at ClinicalTrials.gov, study number: NCT00998556).
Moreover, since not all patients profited equally from the
above-mentioned triple drug therapy concept, further
characterization, such as genetics and risk factor profiles of
different PPCM etiologies, are required for better man-
agement and risk stratification in these patients.
Limitations of our study
Limitations to this study are that 19 PPCM patients with
baseline data were lost to follow-up and that the data
analyzed including the echocardiographic data were
obtained from records provided by physician without
quality control. Minimal requirement for enrolment in this
registry was baseline LVEF and close relationship to
pregnancy (pregnant or delivery up to 6 months ago), not
all patients agreed to provide blood probes and additional
clinical data, a reason why not all other data sets are
complete in this registry. For CRP and TnT, only standard
and no novel high sensitive assays were used. It is
important to note that the results regarding medications,
specifically bromocriptine treatment, derive from a pro-
spective observational analysis and are not based on a
randomized and/or placebo-controlled clinical trial.
In conclusion, the observations gained from this first
Western European prospective cohort study show similar-
ities with the clinical profile described in PPCM patients in
the US with low mortality and a relative high incidence of
recovery, a strong association with gestational hyperten-
sion as a risk factor for the disease and low baseline EF
Fig. 4 Scheme depicting the pathophysiological circuits in PPCM.
Note that Cathepsin D, NT-proBNP, miR-146a and ADMA were
tested as potential biomarkers of PPCM in this study. The scheme
illustrates the release of Prolactin from the pituitary gland towards the
end of pregnancy, which under conditions of enhanced oxidative
stress (ROS) in the myocardium is proteolytically cleaved to a 16 kDa
fragment by Cathepsin D. In healthy myocardium this process is
prevented by antioxidative factors such as MnSOD, which is
regulated by certain transcription factors such as STAT3 and
PGC1-a. The 16 kDa Prolactin leads to increased miR-146a expres-
sion in endothelial cells, which exerts angiotoxic effects and impairs
via an exosome-mediated paracrine fashion the metabolic activity of
cardiomyocytes and the crosstalk between endothelial cells and
cardiomyocytes via down-regulation of ErbB4. An imbalance
between VEGF and the soluble VEGF receptor sFlt as well as
increased ADMA levels add to the anti-angiogenetic effects of the
16 kDa Prolactin-miR-146a axis. Blocking Prolactin with bromocrip-
tine or inhibition of the 16 kDa Prolactin effector miR-146a with
antagomirs prevents or attenuates detrimental effects of 16 kDa
Prolactin. Enhanced levels of pro-inflammatory cytokines such as
IL-6, TNF-a and IFN-c as previously reported point to an additional
inflammatory component within the pathomechanisms of PPCM.
NT-proBNP as an unspecific marker of heart failure is increased in
almost all PPCM patients. ROS reactive oxygen species, MnSOD
manganese Superoxide Dismutase, STAT3 signal transducer and
activator of transcription 3, PGC-1a peroxisome proliferator-acti-
vated receptor gamma, coactivator 1 alpha, sFlt soluble fms-like
tyrosine kinase-1, VEGF vascular endothelial growth factor, IL-6
interleukin-6, TNF-a tumor necrosis factor-a, IFN-c interferon-c,
ADMA asymmetric dimethylarginine
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associated with poor outcome. In addition, it supports the
idea that familial predisposition may be a risk factor in
some patients. It discovered a biomarker profile that sup-
ports the hypothesis of a circuit including unbalanced
oxidative stress, Prolactin cleavage into the anti-angiogenic
16 kDa form and subsequent severe endothelial damage
and dysfunction as a major driving force for PPCM. This
highly specific biomarker profile may help to distinguish
PPCM patients at an early stage from healthy postpartum
women. Finally, the high recovery rate in the present
PPCM collective is associated with the largest series using
a novel therapy concept of a combination of beta-blockers,
ACE inhibitors/ARBs and bromocriptine, a feature that
encourages further testing of potential benefits of this
treatment concept in randomized studies as outlined above.
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